Extra treatment for certain digestive cancers with undetectable ctDNA
Part of Cancer clinical trials.
This trial tests if adding extra local treatments (like surgery or radiation) to usual care can improve outcomes for people with certain advanced digestive cancers that have spread to a limited number of sites. You may be eligible if your cancer has responded well to at least 4 months of therapy and your ctDNA (a sign of cancer in the blood) is undetectable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IV cancer of the esophagus, stomach, pancreas, bile ducts, gallbladder, or duodenum.
- Your primary tumor can be treated with surgery, radiation, or other local therapy.
- Your cancer has spread to no more than 2 places (like liver, lungs, or lymph nodes) that can be completely treated.
- You have had at least 4 months of successful systemic therapy (like chemo) and your ctDNA levels are undetectable on two separate tests.
- You are between 18 and 80 years old, in good general health, and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether giving treatment based on a positive blood test for “minimal cancer signals” (ctDNA) can help people with certain GI cancers stay cancer-free longer. It focuses on people who have finished curative-intent therapy and currently have no visible disease on scans, but their blood test is still positive.
This study tests whether a simple blood test (called ctDNA) can help decide if you need additional chemotherapy after surgery for stomach or esophageal cancer. The goal is to avoid unnecessary treatment for patients who are already cancer-free while ensuring those who need it get the right therapy.
This trial tests whether using a blood test for cancer DNA (ctDNA) can help decide if more chemotherapy is needed after surgery and chemo for advanced stomach cancer. It may help tailor treatment to your individual risk of cancer returning.
This trial tests whether using a blood test for tumor DNA (ctDNA) can help decide who needs more chemotherapy after surgery for advanced stomach cancer. The goal is to personalize treatment and avoid unnecessary side effects.
This trial tests whether treatment for colon cancer after surgery can be guided by a blood test that looks for leftover cancer signals (ctDNA). It may help some people choose stronger or different chemo based on whether ctDNA is found after surgery.
This Phase 1 study uses a blood test called ctDNA to decide whether and how to adjust treatment in people with colon cancer who still have a small amount of disease left after surgery. If your blood test remains positive, the trial aims to reduce recurrence risk by guiding treatment changes.
Hear when a new Esophageal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.